Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 16 June 2017

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

Ablynx    

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

 

GHENT, Belgium, 16 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC on 13 June 2017.

 

FMR LLC (taking into account the holdings of its subsidiary undertakings) currently holds a total of 5,620,583 Ablynx shares, representing 9.19% of the current 61,133,199 outstanding Ablynx shares, slightly increased from 9.14% previously.

 

FMR LLC has notified Ablynx that the shareholding in Ablynx held through financial instruments by FMR Co., Inc., a subsidiary of Fidelity Management & Research Company, which itself is a subsidiary of FMR LLC (the ultimate parent company), has dropped below the 3% threshold as of 9 June 2017.

 

According to the notification, FMR Co., Inc.'s holding of Ablynx shares and voting rights through financial instruments has decreased to 1,827,367 shares, corresponding to 2.99% of the current 61,133,199 outstanding Ablynx shares (versus 3.35% in the previous notification on 28 December 2016).

 

The notified details are presented below:

Name

% of shares and voting rights

% of shares and voting rights held through financial instruments

 

Total of both

Shares

Voting rights

Shares

Voting rights

Shares

Voting rights

FMR LLC

Fidelity Management & Research Company

FMR Co., Inc.

3.61%

3.61%

2.99%

2.99%

6.60%

6.60%

FMR LLC

FIAM Holdings Corp.

Fidelity Institutional Asset Management Trust Company

1.50%

1.50%

 

 

1.50%

1.50%

FMR LLC

FIAM Holdings Corp.

FIAM LLC

1.10%

1.10%

 

 

1.10%

1.10%

TOTAL

 

6.20%

6.20%

2.99%

2.99%

9.19%

9.19%

 

The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.

 

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

 

 

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

 

Lies Vanneste

Director Investor Relations

t:   +32 (0)9 262 01 37

m: +32 (0)498 05 35 79

e:  lies.vanneste@ablynx.com

Follow us on Twitter @AblynxABLX

 

 

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan

t: +44 20 3727 1000

e: ablynx@fticonsulting.com

 

 




pdf version of the press release



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Ablynx, Technologiepark 21, Ghent/Zwijnaarde 9052, België
If you would like to unsubscribe and stop receiving these e-mails click here.